Hanna Kortejärvi - Concepedia

Author

Hanna Kortejärvi

University of Helsinki

Also Known As

H Kortejärvi, H. Kortejärvi, Hanna Kortejärvi

Publications

587

Citations

H-Index

Concepts

All Affiliations

University of Helsinki Orion Corporation (Finland)Islamia University of Bahawalpur

About

Hanna Kortejärvi is an author at University of Helsinki specializing in medicine, pharmacology, and pharmacokinetics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	385
2	Engineering	2	2	123
3	Biomedical Engineering	2	2	62
4	Biomolecular Engineering	1	1	28
5	Biostatistics	1	1	22

Hanna Kortejärvi

Publications

548

Citations

H-Index

Page 1

	Year	Citations
Biowaiver monographs for immediate release solid oral dosage forms: Ranitidine hydrochloride Hanna Kortejärvi, Marjo Yliperttula, Jennifer Dressman, Journal of Pharmaceutical Sciences Pharmaceutical ScienceRanitidine HydrochloridePharmacologyBiowaiver MonographsClinical Pharmacology	2005	103
In Situ Measurement of Solvent-Mediated Phase Transformations During Dissolution Testing Jaakko Aaltonen, Paula Heinänen, Leena Peltonen, Journal of Pharmaceutical Sciences Materials ScienceSolvent ExtractionEngineeringPhase EquilibriumSolution (Chemistry)	2006	101
Pharmacokinetic simulation of biowaiver criteria: The effects of gastric emptying, dissolution, absorption and elimination rates Hanna Kortejärvi, Arto Urtti, Marjo Yliperttula European Journal of Pharmaceutical Sciences Physiologically-based Pharmacokinetic ModelingGastric EmptyingMedicinePharmacokinetic SimulationDrug Absorption	2006	84
Effect of cell differentiation and passage number on the expression of efflux proteins in wild type and vinblastine-induced Caco-2 cell lines Sanna Siissalo, Leena Laitinen, Maija Koljonen, European Journal of Pharmaceutics and Biopharmaceutics Passage NumberCell PhysiologySignal TransductionCell RegulationCell Signaling	2007	55
Patient involvement is essential in identifying drug‐related problems Heini Kari, Hanna Kortejärvi, Marja Airaksinen, British Journal of Clinical Pharmacology	2018	42
Use of conventional surfactant media as surrogates for FaSSIF in simulating in vivo dissolution of BCS class II drugs Paula Lehto, Hanna Kortejärvi, Anni Liimatainen, European Journal of Pharmaceutics and Biopharmaceutics MedicineVivo DissolutionBiomedical EngineeringDrug Delivery SystemPharmacology	2011	40
Development of level A, B and C in vitro–in vivo correlations for modified-release levosimendan capsules Hanna Kortejärvi, Janne Mikkola, M. Bäckman, International Journal of Pharmaceutics Vitro–in Vivo CorrelationsMedicineClinical PharmacologyLevel APharmacology	2002	28
Very rapid dissolution is not needed to guarantee bioequivalence for biopharmaceutics classification system (BCS) I drugs Hanna Kortejärvi, Ramzi Shawahna, Anna Koski, Journal of Pharmaceutical Sciences Pharmaceutical ScienceBioequivalenceDrug DiscoveryPharmacologyPharmaceutical Technology	2009	22
Level A in vitro-in vivo Correlation (IVIVC) Model with Bayesian Approach to Formulation Series Hanna Kortejärvi, J. Malkki, Martti Marvola, Journal of Pharmaceutical Sciences Translational MedicineEngineeringPharmacokinetic ModelingPreclinical Drug EvaluationMedicine	2006	22
Effectiveness and cost-effectiveness of a people-centred care model for community-living older people versus usual care ─ A randomised controlled trial Heini Kari, Nelli Äijö-Jensen, Hanna Kortejärvi, Research in Social and Administrative Pharmacy	2021	20

Page 1